首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis
【2h】

Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis

机译:在败血症诊断时开始的血液净化治疗可有效减轻血清HMGB1的上调并改善患者的预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to investigate the increase in serum and urine levels of high mobility group box protein 1 (HMGB1) during sepsis and the effect of blood purification treatments on HMGB1 levels and patient prognosis. A total of 40 intensive care patients with sepsis were randomly assigned to different groups (n=10 per group): A control group (sepsis group), a continuous renal replacement treatment (CRRT) group, a hemoperfusion (HP) group and an HP+CRRT group. The blood purification treatments using HP and/or CRRT were performed immediately after the diagnosis of sepsis. HMGB1 levels were measured using ELISA, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores and 30-day survival rates were evaluated. Relative to a healthy control group (n=10), HMGB1 levels were observed to be significantly upregulated during sepsis (P<0.05). Following the initiation of sepsis, serum HMGB1 continued to increase in the sepsis group and was significantly elevated at 24 h (P<0.05), whereas urine HMGB1 levels decreased significantly at 12 and 24 h (P<0.05). Serum HMGB1 levels were significantly positively correlated with APACHE II scores (r=0.7284, P<0.01) and significantly negatively correlated with urine HMGB1 levels (r=−0.5103, P=0.026). Serum HMGB1 levels were significantly reduced in the HP and HP+CRRT groups by 12 and 24 h following the initiation of treatment (both P<0.05). Changes in the urine HMGB1 level differed in each group. Relative to the sepsis group, the APACHE II scores of all blood purification groups were significantly reduced (P<0.05) and the 30-day survival rate of the HP+CRRT group was significantly increased (P=0.0107). The results of the present study indicate that blood purification initiated at the point of diagnosis in patients with sepsis may attenuate serum HMGB1 upregulation, promote urinary excretion of HMGB1 and improve the prognosis of sepsis.
机译:本研究的目的是研究败血症期间高迁移率族盒蛋白1(HMGB1)的血清和尿液水平的增加,以及血液净化治疗对HMGB1水平和患者预后的影响。共有40名脓毒症重症监护患者随机分为不同组(每组n = 10):对照组(败血症组),连续肾脏替代治疗(CRRT)组,血液灌流(HP)组和HP + CRRT组。诊断为败血症后立即进行使用HP和/或CRRT的血液净化治疗。使用ELISA测量HMGB1水平,并评估急性生理和慢性健康评估(APACHE)II评分和30天生存率。相对于健康对照组(n = 10),脓毒症期间HMGB1水平显着上调(P <0.05)。脓毒症发作后,脓毒症组血清HMGB1继续增加,并在24 h时显着升高(P <0.05),而尿HMGB1水平在12和24 h时显着下降(P <0.05)。血清HMGB1水平与APACHE II评分显着正相关(r = 0.7284,P <0.01),与尿液HMGB1水平显着负相关(r = -0.5103,P = 0.026)。开始治疗后12和24小时,HP和HP + CRRT组的血清HMGB1水平显着降低(均P <0.05)。每组中尿液HMGB1水平的变化均不同。相对于败血症组,所有血液净化组的APACHE II评分均显着降低(P <0.05),HP + CRRT组的30天生存率显着提高(P = 0.0107)。本研究的结果表明,在脓毒症患者诊断时开始的血液净化可以减弱血清HMGB1的上调,促进HMGB1的尿排泄并改善脓毒症的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号